Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of anti-TSLP (tezepelumab) on airway hyperresponsiveness and mast cell phenotype in asthma
2015-005542-56Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Change in PD15 to mannitol from baseline to post-treatment. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-005542-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005542-56.